Skip to main navigation
Skip to search
Skip to main content
Search by expertise, name or affiliation
TP53 mutations as a biomarker for high-grade serous ovarian cancer: Are we there yet?
Derek B. Oien,
Contribution to journal
Dive into the research topics of 'TP53 mutations as a biomarker for high-grade serous ovarian cancer: Are we there yet?'. Together they form a unique fingerprint.